Life-Science Construction Fell From 25M SF to 5.6M, and 72% Is Pre-Leased

Key Highlights

• The U.S. life-sciences construction pipeline totaled 5.6M sf in Q2 2026, down from more than 25M sf at the Q2 2023 peak, per Cushman and Wakefield (via CRE Direct, Sept 18).
• About 4.5M sf of that pipeline is scheduled to deliver in 2026, and 72% of it is already pre-leased, reflecting build-to-suit dominance.
• Roche and Genentech opened a 95,000-sf innovation center in Allston on a 10-year lease, anchoring phase one of the nine-acre Enterprise Research Campus next to Harvard (Connect CRE, Sept 18); the space holds up to 500 people.
• The pipeline is now roughly a fifth of peak; what remains is largely committed before completion.

The Signal

• A 78% pipeline contraction in three years is the fastest supply correction of any CRE sector this cycle.
• 72% pre-leased on 2026 deliveries means the vacancy overhang is in existing spec buildings, not in what is coming.
• Roche's 95,000-sf, 10-year commitment is the demand profile that gets built now: a credit pharma tenant, a fixed term, a campus setting.

What is happening: the life-sciences development boom that peaked at more than 25M sf under construction in mid-2023 has unwound to 5.6M sf, and most of what is left was pre-committed by a tenant before the shell was finished.

Why it matters: the sector's problem was never demand for lab space in the abstract; it was 25M sf of speculative lab space built against venture-funded tenants who stopped raising money. Removing the spec pipeline is the necessary condition for existing vacancy to burn off, and that condition has now been met.

The Allston lease is the model. Roche and Genentech did not take a floor in a converted office building; they anchored the first phase of a university-adjacent research campus on a decade-long term. Build-to-suit for pharma credit is the only lab construction that lenders are financing at scale.

The structural read: life sciences is transitioning from a development asset class back to a leasing asset class. Rents on existing product will keep adjusting until the 2021 through 2023 deliveries fill; new starts will be tenant-led and pre-leased, and the spread between committed and spec lab will widen.

Caution: the 5.6M sf and 72% figures are national aggregates; Boston, San Francisco and San Diego each carry different vacancy and absorption profiles.

Implications

• For lab owners with spec vacancy: the supply competition ahead is minimal; the competition is the existing 2022 and 2023 deliveries still in lease-up.
• For developers: a lab start without a signed anchor is not a financeable project in 2026.
• For institutional buyers: stabilized, credit-anchored lab campuses are scarce and pre-leased pipeline is small; that combination supports pricing on the assets that exist.

Life sciences did not stop building; it stopped building without a tenant.